LB Pharmaceuticals, Inc. (LBRX)
48.80
+0.59
(+1.22%)
USD |
NASDAQ |
Aug 25, 16:00
48.78
-0.02
(-0.04%)
After-Hours: 19:59
LB Pharmaceuticals Enterprise Value : 1.077B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 1.077B |
| August 24, 2026 | 1.060B |
| August 21, 2026 | 1.043B |
| August 20, 2026 | 1.032B |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.076B |
| August 17, 2026 | 1.003B |
| August 14, 2026 | 1.048B |
| August 13, 2026 | 947.14M |
| August 12, 2026 | 978.98M |
| August 11, 2026 | 977.54M |
| August 10, 2026 | 992.46M |
| August 07, 2026 | 1.054B |
| August 06, 2026 | 1.059B |
| August 05, 2026 | 968.94M |
| August 04, 2026 | 968.08M |
| August 03, 2026 | 906.13M |
| July 31, 2026 | 826.97M |
| July 30, 2026 | 850.48M |
| July 29, 2026 | 795.99M |
| July 28, 2026 | 679.54M |
| July 27, 2026 | 674.96M |
| July 24, 2026 | 681.55M |
| July 23, 2026 | 670.37M |
| July 22, 2026 | 705.36M |
| Date | Value |
|---|---|
| July 21, 2026 | 604.11M |
| July 20, 2026 | 563.67M |
| July 17, 2026 | 578.30M |
| July 16, 2026 | 554.78M |
| July 15, 2026 | 599.81M |
| July 14, 2026 | 595.80M |
| July 13, 2026 | 602.39M |
| July 10, 2026 | 622.47M |
| July 09, 2026 | 645.13M |
| July 08, 2026 | 657.46M |
| July 07, 2026 | 660.90M |
| July 06, 2026 | 635.66M |
| July 02, 2026 | 636.24M |
| July 01, 2026 | 592.07M |
| June 30, 2026 | 608.27M |
| June 29, 2026 | 573.78M |
| June 26, 2026 | 553.13M |
| June 25, 2026 | 526.75M |
| June 24, 2026 | 511.84M |
| June 23, 2026 | 515.28M |
| June 22, 2026 | 494.35M |
| June 18, 2026 | 498.08M |
| June 17, 2026 | 499.51M |
| June 16, 2026 | 430.98M |
| June 15, 2026 | 455.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 5.386B |
| Neumora Therapeutics, Inc. | 216.69M |
| ANI Pharmaceuticals, Inc. | 1.972B |
| Corcept Therapeutics, Inc. | 13.04B |
| Veru, Inc. | 23.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.60M |
| Total Expenses (Quarterly) | 51.60M |
| EPS Diluted (Quarterly) | -1.712 |
| Earnings Yield | -6.11% |
| Normalized Earnings Yield | -6.120 |